Survodutide research peptide 10mg vial by Apeptide Biotech for laboratory research use

Survodutide Peptide: Benefits, Research, Dosage Information and Where to Buy

Survodutide peptide, also identified by the development code BI 456906, is an investigational compound being studied for its activity at both the glucagon receptor and the glucagon-like peptide-1 receptor. This dual-receptor profile has made it an important subject in metabolic, energy-balance, body-composition and liver-related research.

Unlike semaglutide, which primarily activates the GLP-1 receptor, survodutide combines GLP-1 receptor activity with glucagon receptor activity. Researchers are studying whether this combination can influence appetite-related signaling, energy expenditure, fat metabolism and metabolic liver pathways.

This guide explains what survodutide is, how its dual-receptor activity works, its current research status, comparisons with related compounds and important laboratory purchasing considerations.

Research notice: Survodutide is an investigational substance. Products supplied by Apeptide Biotech are intended strictly for qualified laboratory research and analytical testing. They are not medicines, supplements or products for human consumption.

Table of Contents

What Is Survodutide?

Survodutide peptide is a glucagon receptor and GLP-1 receptor dual agonist developed under the research name BI 456906. It was originally developed through work involving Zealand Pharma and is being advanced clinically by Boehringer Ingelheim. Current research programs include obesity, overweight and metabolic dysfunction-associated steatohepatitis.

GLP-1 is an incretin hormone associated with glucose-dependent signaling, appetite regulation and gastric-emptying pathways. Glucagon is involved in glucose availability, lipid metabolism and energy expenditure. Survodutide combines activity at both receptors within one investigational molecule.

This mechanism distinguishes it from single-receptor GLP-1 compounds and from GIP-based dual or triple agonists.

How Does Survodutide Work?

The proposed research activity of survodutide involves two complementary receptor pathways.

GLP-1 Receptor Activity

Activation of GLP-1 receptors is studied in connection with appetite-related signaling, glucose-dependent insulin responses, glucagon regulation and gastric emptying. These pathways can influence food intake and metabolic measurements under controlled research conditions.

Glucagon Receptor Activity

Glucagon receptor activation is associated with hepatic energy metabolism, lipid mobilization and energy expenditure. Researchers are particularly interested in how carefully balanced glucagon receptor activity may affect liver fat and visceral adipose tissue.

Dual-Receptor Research

By activating both receptor systems, survodutide peptide is intended to combine GLP-1-associated appetite effects with glucagon-associated metabolic activity. The exact balance, long-term effects and clinical significance remain subjects of ongoing investigation.

Survodutide Research Applications

Metabolic Signaling Studies

Survodutide may be used as a reference compound in studies examining GLP-1 and glucagon receptor activation, downstream signaling pathways and metabolic responses.

Body-Composition Research

Clinical and preclinical researchers have studied the compound in relation to body weight, waist measurements, visceral adipose tissue and the preservation of lean tissue. These findings apply to specific trial conditions and should not be interpreted as guaranteed outcomes.

Liver and MASH Research

The glucagon component has generated research interest in liver-fat metabolism. Survodutide is being evaluated in Phase 3 LIVERAGE studies involving people with MASH and liver fibrosis.

Comparative Receptor Research

Researchers may compare survodutide with single GLP-1 agonists, GIP/GLP-1 dual agonists and triple receptor agonists to understand how different receptor combinations affect cellular and metabolic models.

Published Clinical Research

A randomized Phase 2 study evaluated survodutide in adults with obesity. The study identified survodutide as a glucagon receptor and GLP-1 receptor dual agonist and assessed its safety, tolerability and effects under a controlled clinical protocol.

The Phase 3 SYNCHRONIZE-1 study subsequently evaluated once-weekly survodutide in adults with obesity who did not have diabetes. Published results reported significantly greater average body-weight reductions with survodutide than with placebo after 76 weeks.

Boehringer Ingelheim reported an average reduction of up to 16.6% in the principal Phase 3 analysis, compared with 3.2% for placebo. These were clinical-trial findings involving a specific investigational formulation, dose-escalation protocol and monitored population. They must not be treated as instructions for research-grade products.

Scientific Reference Links

Survodutide Dosage and Concentration Information

Searches for survodutide dosage, dosing schedules and reconstitution instructions are common. However, survodutide peptide remains investigational, and this page does not provide human dosing or injection instructions.

Published clinical trials used controlled dose-escalation schedules, pharmaceutical investigational products and continuous medical oversight. Those schedules must not be transferred to research-grade material.

Laboratory concentration decisions should be based on:

  • The experimental model
  • The study objective
  • Compound purity and molecular weight
  • Published experimental methods
  • Institutional laboratory procedures
  • Validated concentration calculations

Researchers should establish an approved protocol before handling or preparing any investigational peptide.

Safety and Tolerability Research

Clinical research has reported gastrointestinal events such as nausea, vomiting and diarrhea among participants receiving survodutide. Discontinuations related to adverse events were also observed in the Phase 3 program. These findings remain part of the ongoing evaluation of the compound’s benefit-risk and tolerability profile.

Laboratory research materials introduce separate risks involving handling, measurement accuracy, contamination, storage and compound identification. Appropriate personal protective equipment and institutional safety procedures should always be used.

Apeptide Biotech research material must not be administered to humans or animals and must not be substituted for an approved medicine.

Survodutide Compared With Other Peptides

Compound Primary Receptor Profile Research Classification
Survodutide Glucagon and GLP-1 Investigational dual agonist
Semaglutide GLP-1 Single GLP-1 receptor agonist
Tirzepatide GIP and GLP-1 Dual incretin receptor agonist
Retatrutide GIP, GLP-1 and glucagon Investigational triple agonist
Cagrilintide Amylin and calcitonin receptors Investigational amylin analogue

Survodutide vs Semaglutide

Semaglutide primarily activates GLP-1 receptors. Survodutide activates both GLP-1 and glucagon receptors, adding a second metabolic signaling pathway.

Survodutide vs Tirzepatide

Tirzepatide combines GIP and GLP-1 receptor activity. Survodutide does not principally target GIP receptors; it combines GLP-1 with glucagon receptor activation.

Survodutide vs Retatrutide

Retatrutide is a triple agonist involving GIP, GLP-1 and glucagon receptors. Survodutide is a dual agonist involving GLP-1 and glucagon receptors.

Where to Buy Survodutide for Research

Qualified researchers looking to buy survodutide peptide should evaluate product identity, purity, batch traceability, packaging and analytical documentation rather than relying only on the advertised vial quantity.

Apeptide Biotech supplies research peptides and related materials to laboratories, research professionals and distributors. Available concentrations, packaging formats and supporting documentation may vary by production batch.

Before ordering, confirm:

  • Declared compound identity
  • Quantity per vial
  • Available purity documentation
  • Batch or lot information
  • Storage recommendations
  • Research-use-only labeling
  • Import and laboratory requirements in your jurisdiction

Visit the Apeptide Biotech peptide shop to review available research materials, or learn more about our sourcing and supply services on the Apeptide Biotech homepage.

Frequently Asked Questions About Survodutide

What is survodutide?

Survodutide is an investigational peptide that activates both glucagon and GLP-1 receptors. Its research development code is BI 456906.

What category of peptide is survodutide?

It is categorized as a glucagon and GLP-1 receptor dual agonist and a metabolic research compound.

Is survodutide approved by the FDA?

Survodutide remains investigational as of July 2026. It is being evaluated in Phase 3 clinical development programs and should not be presented as an approved prescription medicine.

Is survodutide the same as semaglutide?

No. Semaglutide primarily activates GLP-1 receptors, while survodutide activates both GLP-1 and glucagon receptors.

Is survodutide the same as retatrutide?

No. Survodutide is a dual agonist, while retatrutide is an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors.

What is BI 456906?

BI 456906 is the research development code used for survodutide in scientific publications and registered clinical trials.

Is survodutide being studied for MASH?

Yes. Phase 3 LIVERAGE trials are evaluating the compound in people with MASH and liver fibrosis.

Does this page provide a survodutide dosage chart?

No. This page does not provide dosing, injection or reconstitution instructions. Laboratory concentrations must be determined through a validated research protocol.

Where can researchers purchase survodutide?

Qualified laboratories and research professionals can check availability through the Apeptide Biotech research shop.

Conclusion

Survodutide peptide is an important investigational compound in glucagon and GLP-1 receptor research. Its dual-receptor mechanism distinguishes it from semaglutide, tirzepatide and retatrutide and supports ongoing study in metabolic, body-composition and liver-related research.

Researchers should rely on peer-reviewed publications, validated experimental methods and complete analytical documentation when designing studies involving BI 456906.

Explore high-quality research peptides and laboratory supply solutions through the Apeptide Biotech shop.

Disclaimer: For laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure or prevent any disease. Survodutide is an investigational compound, and nothing on this page constitutes medical advice.